本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 江苏康缘药业股份有限公司（以下简称"公司"）近日收到国家药品监督管 理局核准签发的关于 KYS202002A 注射液成人系统性红斑狼疮适应症的《药物 临床试验批准通知书》。KYS202002A 是由公司开发的一种全人源抗 CD38 单克 隆抗体，该新药前期已在中国、美国获得复发和难治性多发性骨髓瘤适应症临床 研究许可，相关情况详见公司分别于 2023 年 1 月 11 日、2023 年 6 月 27 日在上 海证券交易所网站 www.sse.com.cn 披露的公司《关于收到 KYS202002A 注射液 临床试验批准通知书的公告》（公告编号：2023-003）、《关于 KYS202002A 注 射液获得美国 FDA 临床试验批准的公告》（公告编号：2023-025），目前已启动 中国复发和难治性多发性骨髓瘤适应症 I 期临床研究。本次获批成人系统性红斑 狼疮适应症《药物临床试验批准通知书》相关情况如下： 证券简称：康缘药业 证券代码：600557 公告编号：2023-03 ...

证券代码：600557 证券简称：康缘药业 公告编号：2023-032 江苏康缘药业股份有限公司 2022 年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利 0.22 元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2023/8/22 | － | 2023/8/23 | 2023/8/23 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司 2023 年 6 月 26 日的 2022 年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2022 年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本 584, ...

Financial Performance - Total operating revenue for the first half of 2023 reached ¥2,553,167,904.18, an increase of 21.7% compared to ¥2,097,177,339.38 in the same period of 2022[11]. - Net profit for the first half of 2023 was ¥334,746,398.79, compared to ¥251,195,552.65 in the first half of 2022, representing a growth of 33.2%[11]. - The company's operating revenue for the first half of 2023 reached CNY 2,410,524,559.94, representing a 23.2% increase from CNY 1,954,559,561.41 in the same period of 2022[15]. - Net profit attributable to shareholders of the parent company was CNY 275,720,868.32, up 30.6% from CNY 211,120,583.32 year-on-year[12]. - Total comprehensive income for the period was CNY 282,889,034.97, compared to CNY 211,364,180.66 in the first half of 2022, marking a 33.8% increase[12]. Assets and Liabilities - As of June 30, 2023, the total current assets amounted to CNY 3,771,501,855.17, a slight increase from CNY 3,729,859,645.62 as of December 31, 2022, representing a growth of approximately 1.1%[2]. - The total non-current assets decreased to CNY 3,032,851,520.74 from CNY 3,065,944,555.74, indicating a decline of about 1.1%[3]. - The total assets of the company reached CNY 6,804,353,375.91, up from CNY 6,795,804,201.36, reflecting a marginal increase of approximately 0.1%[4]. - Total liabilities decreased to CNY 1,694,500,889.52 from CNY 1,861,811,589.74, showing a reduction of about 9%[4]. - The total equity attributable to shareholders increased to CNY 4,925,246,004.02 from CNY 4,754,194,495.90, marking an increase of approximately 3.6%[4]. Cash Flow - The company's operating cash inflow for the first half of 2023 was CNY 2,979,346,456.08, an increase of 25.7% compared to CNY 2,370,291,696.69 in the same period of 2022[22]. - The net cash flow from operating activities was CNY 456,366,532.43, up from CNY 374,551,870.05 in the first half of 2022, representing a growth of 21.9%[22]. - The total cash and cash equivalents at the end of the period reached CNY 1,977,320,416.17, up from CNY 957,364,934.32 at the end of the first half of 2022[24]. Research and Development - Research and development expenses increased to ¥363,451,324.29 in the first half of 2023, compared to ¥277,402,732.74 in the same period of 2022, marking a rise of 31%[11]. - Research and development expenses amounted to CNY 350,669,094.98, which is a 33.0% increase from CNY 263,637,771.87 in the first half of 2022[15]. - The company has established an advanced innovative drug research and development system, focusing on developing innovative drugs with clinical advantages and characteristics[68]. Market and Product Development - The company plans to continue expanding its market presence and investing in new product development to sustain growth[20]. - The company is focused on innovation in traditional Chinese medicine and actively expanding into chemical and biological pharmaceuticals[52]. - The company has a diverse product line targeting respiratory, gynecological, cardiovascular, and orthopedic diseases, with several new drugs under development[52]. - The company plans to launch three new products in the next quarter, focusing on innovative drug formulations[161]. Corporate Governance - The board of directors was expanded from 7 to 9 members, and the supervisory board from 3 to 5 members, to enhance corporate governance[198]. - The company has completed the election of the board of directors and supervisory board, as well as the appointment of senior management[200]. - The company is focusing on improving its internal governance structure to align with its growth objectives[198]. Strategic Initiatives - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[105]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach, with a budget of CNY 500 million allocated for this purpose[108]. - Future guidance indicates a revenue target of CNY 2.5 billion for the full year 2023, representing a growth rate of 12%[104]. Quality Control and Compliance - The company has established a strict quality control mechanism for its products, ensuring that raw materials meet higher internal standards than legal requirements[138]. - The company emphasizes the importance of accurate measurement and reporting of financial assets and liabilities to mitigate accounting mismatches[63]. - The company has implemented a systematic approach to amortize contract costs, ensuring that costs related to contract performance are recognized as assets when they meet specific criteria[148].

证券简称：康缘药业 证券代码：600557 公告编号：2023-013 江苏康缘药业股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可以在 2023 年 5 月 10 日(星期三)至 5 月 12 日(星期五)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过 公司邮箱 （fzb@kanion.com）进行提问，公司将在说明会上就投资者普遍关注的问题进行 解答。 一、说明会类型 江苏康缘药业股份有限公司（以下简称"公司"）于 2023 年 2 月 21 日在 《上海证券报》《中国证券报》《证券日报》《证券时报》及上海证券交易所 网站www.sse.com.cn披露了《江苏康缘药业股份有限公司 2022 年年度报告》， 于 2023 年 4 月 8 日在《上海证券报》《中国证券报》《证券日报》《证券时 报》及上海证券交易所网站www.sse.com.cn披露了《江苏康缘药业股份有限公 司 2023 年第 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 1,352,493,841.95, representing a 25.39% increase year-over-year[19]. - The net profit attributable to shareholders for Q1 2023 was CNY 141,438,358.86, reflecting a 28.60% increase compared to the same period last year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 139,362,939.64, up 30.70% year-over-year[19]. - The basic earnings per share for Q1 2023 was CNY 0.25, an increase of 31.58% compared to the previous year[19]. - The diluted earnings per share for Q1 2023 was CNY 0.24, reflecting a 26.32% increase year-over-year[19]. - Net profit for Q1 2023 was ¥145,272,114.36, compared to ¥110,378,236.08 in Q1 2022, representing a 31.6% growth[45]. - Total comprehensive income amounts to 145,272,114.36, an increase from 110,378,236.08[49]. - Total comprehensive income attributable to the parent company is 141,438,358.86, up from 109,985,159.38[49]. Cash Flow and Assets - The net cash flow from operating activities was CNY -60,672,699.77, a decrease of 176.67% compared to the same period last year[19]. - Cash flow from operating activities in Q1 2023 showed a net outflow of ¥60,672,699.77, compared to a net inflow of ¥79,139,904.88 in Q1 2022[46]. - The total assets at the end of Q1 2023 were CNY 6,718,199,483.33, a decrease of 1.14% from the end of the previous year[19]. - The total assets as of Q1 2023 were ¥6,718,199,483.33, down from ¥6,795,804,201.36 in the previous year[43]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,177, with Jiangsu Kangyuan Group Co., Ltd. holding 30.14% of shares[25]. - The equity attributable to shareholders at the end of Q1 2023 was CNY 4,895,632,854.76, representing a 2.98% increase from the end of the previous year[19]. - The total equity attributable to shareholders of the parent company is 4,895,632,854.76 RMB, an increase from 4,754,194,495.90 RMB[29]. Liabilities - The total liabilities amount to 1,641,294,557.35 RMB, down from 1,861,811,589.74 RMB in the previous period[29]. - The company’s total liabilities decreased from ¥1,781,105,699.00 in the previous year to ¥1,561,334,431.09 in Q1 2023, a decline of approximately 12.3%[43]. - The total non-current liabilities amount to 79,960,126.26 RMB, slightly down from 80,705,890.74 RMB[29]. Research and Development - Research and development expenses in Q1 2023 amounted to ¥188,577,937.82, an increase from ¥144,196,379.61 in Q1 2022, indicating a 30.8% rise[44]. Other Financial Information - The company recorded a government subsidy of 4,035,535.94 RMB, which is closely related to its normal business operations[21]. - The company experienced a loss of 253,015.40 RMB from the disposal of non-current assets[21]. - The company’s investment income for Q1 2023 was ¥447,980.55, down from ¥1,127,010.39 in Q1 2022, reflecting a decrease of 60.3%[44]. - The net profit attributable to the parent company's shareholders is 141,438,358.86, up from 109,985,159.38[49]. - The net profit attributable to minority shareholders is 3,833,755.50, compared to 393,076.70 previously[49]. - The company did not apply new accounting standards or interpretations starting in 2023[51].

Share Capital and Financial Performance - The company issued a total of 584,597,952 shares by the end of 2022, a decrease of 8,283,086 shares compared to the beginning of the year[2]. - As of December 31, 2022, the company's distributable profit amounted to ¥3,843,349,759.05[198]. - The total share capital as of December 31, 2022, was 584,597,952 shares[198]. - The board proposed a cash dividend of ¥2.20 per 10 shares (tax included), totaling approximately ¥128,611,549.44 to be distributed to shareholders[198]. - The company achieved a consolidated revenue of CNY 4,350.87 million, representing a year-on-year increase of 19.25%[60]. - The net profit attributable to shareholders increased by 35.54% to CNY 434.47 million[60]. - The company reported a weighted average return on equity of 9.61%, an increase of 2.04 percentage points year-on-year[60]. - Total operating cash flow for the period was approximately ¥995.94 million, an increase of 9.65% compared to the previous year[47]. - The company’s cash and cash equivalents at the end of the period amounted to ¥1,601.30 million, representing 23.56% of total assets, a 70.82% increase from the previous year[48]. - The company achieved a net profit of CNY 300 million, which is a 20% increase compared to the previous year[179]. Research and Development - The company invested significantly in R&D, with a notable increase in prepayments for R&D expenses, contributing to an 86.49% rise in prepayments compared to the previous year[49]. - Research and development expenses totaled CNY 621.17 million, accounting for 14.28% of total revenue[69]. - The company has a strong R&D team, consisting of 203 master's degree holders and 18 doctoral researchers[46]. - The company is committed to strengthening its research and development capabilities by building specialized research teams and enhancing quality control processes[117]. - The company has established a technical committee composed of industry experts to enhance the R&D team and improve the drug development process[120]. - The company is actively pursuing major scientific research projects and enhancing intellectual property protection to build innovation barriers[91]. - The company aims to achieve breakthroughs in innovative drug development in major diseases and other areas aligned with its sales model[26]. - The company is investing heavily in R&D, with a budget allocation of 200 million yuan for the development of new traditional Chinese medicine products[135]. Market and Sales Performance - The company achieved strong growth in core products, focusing on Ginkgo Biloba Terpene Lactone Injection and Jin Zhen Oral Liquid, breaking the previous dominance of Heat Toxicity Ning Injection[9]. - The company's revenue from domestic sales in the industrial sector reached CNY 4,323,415,556.38, representing a year-on-year increase of 19.64%[37]. - The revenue from injectable and oral liquid products was CNY 1,451,284,288.00 and CNY 1,122,387,070.56, with respective gross profit margins of 73.61% and 80.07%[37]. - The sales revenue of gel products increased by 417.69% year-on-year, primarily due to the growth in sales of muscle and joint pain relief gel[38]. - The revenue from oral liquid products surged by 68.45%, driven by increased sales of Jinzhen oral liquid[63]. - The company is focused on maintaining steady revenue and profit growth by leveraging its diverse product portfolio and improving management practices[93]. - The company aims to enhance sales growth by focusing on core products and expanding its OTC business, targeting major retail chains[90]. - Future outlook indicates a projected revenue growth of 10% for 2023, driven by new product launches and market expansion strategies[135]. Operational Efficiency and Management - The company has established a comprehensive production plan based on sales forecasts and real-time inventory, ensuring optimized resource allocation[27]. - The company has implemented a digital extraction and refining factory, recognized as a pilot demonstration project by the Ministry of Industry and Information Technology[34]. - The company’s intelligent manufacturing project has set a benchmark for the transformation of traditional Chinese medicine manufacturing to intelligent production[33]. - The company has implemented advanced quality control technologies throughout the production process to ensure the stability and safety of its products[147]. - The company is focused on mitigating drug quality risks through improved management practices across the supply chain[119]. - The company has implemented a comprehensive upgrade of its ERP system to improve operational management and supply chain efficiency[92]. - The company aims to improve operational efficiency, targeting a 10% reduction in production costs through process optimization[135]. Corporate Governance and Compliance - The company has implemented strict insider information management protocols to ensure compliance during the reporting period[127]. - The company has established a comprehensive information disclosure system to prevent selective disclosure and insider trading, ensuring all shareholders have equal access to information[151]. - The company has adhered to legal requirements in convening shareholder meetings, ensuring equal rights for all shareholders, especially minority shareholders[122]. - The company has not reported any measures affecting its independence from controlling shareholders[128]. - The company maintains independence from its controlling shareholder in operations, finance, and business, ensuring fair and reasonable related party transactions[150]. - The company assures that the annual report's financial statements are true, accurate, and complete[197]. Strategic Initiatives and Future Plans - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[135]. - The company is advancing research on already listed products to build a robust evidence chain for clinical and foundational studies, while also pursuing international drug registration for traditional Chinese medicine[144]. - The company aims to align its social responsibility with competitive advantages to achieve coordinated development in economic, social, and environmental benefits[115]. - The company plans to launch three new products in the upcoming quarter, targeting unmet medical needs[179]. - The company has set a target to launch at least five new products in the next fiscal year, focusing on innovative herbal formulations[135]. - A strategic partnership with a leading research institution has been established to enhance product efficacy and safety[135]. - The company is committed to sustainability initiatives, allocating CNY 50 million for environmental projects[179]. Industry Trends and Market Conditions - The total healthcare expenditure in China reached RMB 7.6845 trillion in 2021, growing approximately fourfold over the past decade, indicating a robust market for the pharmaceutical industry[18]. - The pharmaceutical industry in China has seen a nearly sixfold increase in asset scale over the past ten years, with a compound annual growth rate of 20.4%[18]. - The pharmaceutical industry is significantly influenced by government policies, with ongoing centralized procurement measures expected to impact the market[146].

Financial Performance - The company's operating revenue for Q3 2022 was ¥1,028,314,291.81, representing a 26.25% increase compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2022 was ¥70,217,175.01, an increase of 47.48% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥61,245,927.71, reflecting a 38.70% increase compared to the previous year[5]. - Total operating revenue for the first three quarters of 2022 reached CNY 3,125,491,631.19, an increase of 21% compared to CNY 2,583,608,207.75 in the same period of 2021[22]. - Net profit for the third quarter of 2022 was CNY 283,974,013.13, up 35% from CNY 210,413,540.55 in the third quarter of 2021[24]. - Basic earnings per share for Q3 2022 were CNY 0.49, up from CNY 0.36 in Q3 2021, indicating a 36% increase[26]. Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥6,153,703,406.73, a 2.25% increase from the end of the previous year[6]. - The total assets of the company as of September 30, 2022, were RMB 6,153,703,406.73, compared to RMB 6,018,019,235.83 at the end of 2021, marking a growth of about 2.2%[18]. - The total liabilities decreased to CNY 1,393,009,092.14 in Q3 2022 from CNY 1,545,298,934.37 in Q3 2021, a reduction of approximately 10%[21]. - The company's total equity increased to CNY 4,760,694,314.59 in Q3 2022, compared to CNY 4,472,720,301.46 in Q3 2021, reflecting a growth of about 6%[21]. Cash Flow - The company reported a cash flow from operating activities of ¥612,508,012.74 for the year-to-date, a decrease of 10.37% compared to the previous year[5]. - Cash flow from operating activities for the first three quarters of 2022 was CNY 3,506,264,851.49, compared to CNY 3,223,675,434.45 in the same period of 2021, marking an increase of 9%[26]. - The net cash flow from operating activities for Q3 2022 was CNY 612,508,012.74, a decrease of 10.4% compared to CNY 683,361,113.13 in Q3 2021[27]. - Total cash inflow from operating activities reached CNY 3,662,711,565.24, up 8.7% from CNY 3,367,959,216.39 in the same period last year[27]. - Cash outflow from operating activities was CNY 3,050,203,552.50, an increase of 13.6% compared to CNY 2,684,598,103.26 in Q3 2021[27]. Shareholder Information - The company has a total of 30,074 common shareholders at the end of the reporting period[9]. - The largest shareholder, Jiangsu Kangyuan Group Co., Ltd., holds 30.14% of the shares[9]. Research and Development - Research and development expenses for the first three quarters of 2022 amounted to CNY 437,120,488.39, representing a 30% increase from CNY 336,806,040.18 in the same period of 2021[22]. Inventory and Receivables - The company's inventory decreased to RMB 236,822,438.27 from RMB 338,077,195.06, reflecting a decline of approximately 30%[16]. - Accounts receivable rose to RMB 768,709,052.89, up from RMB 732,061,053.66, indicating an increase of approximately 5%[16]. Financial Management - The company reported a financial expense of CNY -5,239,101.37 in the first three quarters of 2022, a significant improvement compared to CNY 7,282,044.93 in the same period of 2021[22]. - The net cash flow from investing activities was -CNY 195,128,177.52, an improvement from -CNY 233,639,277.64 in Q3 2021[27]. - The net cash flow from financing activities was -CNY 168,289,256.11, an improvement from -CNY 438,458,725.39 in the same quarter last year[29].

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 2,097,177,339.38, representing an increase of 18.54% compared to CNY 1,769,117,489.87 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was CNY 211,120,583.32, up 32.35% from CNY 159,514,513.76 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was CNY 202,088,459.55, which is a 24.21% increase from CNY 162,697,450.54 in the same period last year[21]. - Basic earnings per share for the first half of 2022 were CNY 0.37, an increase of 32.14% compared to CNY 0.28 in the same period last year[21]. - The weighted average return on net assets was 4.79%, up by 1.00 percentage points from 3.79% in the previous year[21]. - The total comprehensive income for the first half of 2022 was CNY 208,178,420.85, compared to CNY 154,798,534.15 in the same period of 2021, representing an increase of approximately 34.4%[146]. - The company reported a profit margin of approximately 10.1% for the first half of 2022, up from 9.1% in the previous year[143]. Cash Flow and Assets - The net cash flow from operating activities was CNY 374,551,870.05, a decrease of 9.59% compared to CNY 414,279,605.72 in the previous year[21]. - The total assets at the end of the reporting period were CNY 6,001,672,130.09, a slight decrease of 0.27% from CNY 6,018,019,235.83 at the end of the previous year[21]. - The total current assets increased to CNY 2,913,381,193.51 from CNY 2,874,218,782.31, reflecting a growth of approximately 1.5%[133]. - Cash and cash equivalents at the end of the period amounted to CNY 957,364,934.32, up from CNY 937,438,231.85, indicating an increase of about 2.0%[133]. - The company's accounts receivable rose to CNY 759,909,387.52 from CNY 732,061,053.66, representing an increase of approximately 3.8%[133]. - Inventory decreased to CNY 278,991,296.88 from CNY 338,077,195.06, showing a decline of about 17.5%[133]. Research and Development - The company has established an advanced drug R&D system, aiming for breakthroughs in innovative drug development, particularly in major diseases[27]. - Research and development expenses increased by 28.01% to ¥277,402,732.74 from ¥216,704,292.91 in the previous year[51]. - The company received 740 new Chinese medicine registration applications in the first half of 2022, a significant increase of 85% year-on-year[34]. - The company holds 571 authorized invention patents and has 52 new Chinese medicines, leading the domestic industry[38]. - The company is recognized as a national technology innovation demonstration enterprise and a key high-tech enterprise, emphasizing its commitment to innovation[25]. Market and Sales - The company operates in the pharmaceutical manufacturing industry, focusing on the R&D, production, and sales of traditional Chinese medicine and other pharmaceutical products[25]. - The company’s sales model includes academic promotion, agency distribution, and mass drug sales, enhancing product visibility and market coverage[31]. - The company achieved significant sales growth in core products, including Jin Zhen Oral Liquid and Xing Bei Cough Granules, despite challenges from the COVID-19 pandemic[48]. Environmental and Social Responsibility - The company is classified as a key pollutant discharge unit by local environmental protection authorities, with no environmental pollution incidents reported during the reporting period[77]. - The company has established two wastewater treatment plants with a total treatment capacity of 3,200 tons per day, ensuring compliance with the GBT/31962-2015-B standard for wastewater discharge[87]. - Jiangsu Kangyuan Pharmaceutical Co., Ltd. invested a total of 74.00 million yuan in poverty alleviation efforts during the reporting period[106]. - The company allocated 19.00 million yuan specifically for targeted poverty alleviation work[106]. - Charitable disaster relief contributions amounted to 275.57 million yuan[106]. Corporate Governance and Management - The company held its first extraordinary general meeting of 2022 on January 28, with 239,331,686 shares represented, accounting for 41.52% of voting shares[66]. - The company appointed several new executives, including vice presidents and a financial director, to strengthen its management team[69]. - The company did not propose any profit distribution or capital reserve increase for the half-year report[74]. - The company confirmed the list of initial recipients for the restricted stock incentive plan on May 30, 2022, with no objections received during the public notice period[75]. Risks and Challenges - The company has not reported any significant risks that could materially affect its operations during the reporting period[7]. - The company faces significant market access risks due to stringent policies and regulations since 2018, which may hinder development[59]. - The company is adapting to regulatory changes by enhancing product quality and improving operational management to maintain market competitiveness[63]. Financial Reporting and Compliance - The company retained the auditing firm Lixin Certified Public Accountants for the 2022 financial report[113]. - There were no significant lawsuits or arbitration matters reported during the period[113]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[104]. - The company's financial statements are prepared in accordance with the accounting standards issued by the Ministry of Finance, ensuring a true and complete reflection of its financial status[182].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 1,078,624,792.24, representing a year-on-year increase of 25.16%[5] - The net profit attributable to shareholders of the listed company was CNY 109,985,159.38, up 30.94% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 106,630,369.84, reflecting a 34.69% increase year-on-year[5] - The basic earnings per share for the period was CNY 0.19, an increase of 26.67% compared to the previous year[5] - Total operating revenue for Q1 2022 reached CNY 1,078,624,792.24, a 25.2% increase from CNY 861,784,479.53 in Q1 2021[25] - Net profit for Q1 2022 was CNY 110,378,236.08, representing a 29.2% increase compared to CNY 85,495,310.26 in Q1 2021[26] - Earnings per share for Q1 2022 were CNY 0.19, up from CNY 0.15 in Q1 2021[28] - The company reported a comprehensive income attributable to shareholders of the parent company of CNY 109,985,159.38 in Q1 2022, compared to CNY 83,997,468.15 in Q1 2021[28] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 5,984,972,937.48, a decrease of 0.55% from the end of the previous year[7] - The company's total assets were CNY 5,984,972,937.48 in Q1 2022, slightly down from CNY 6,018,019,235.83 in Q1 2021[25] - The company's cash and cash equivalents decreased to approximately RMB 721.91 million from RMB 937.44 million year-over-year, reflecting a decline of about 23%[20] - The company's total liabilities decreased to approximately RMB 1.31 billion from RMB 1.45 billion, reflecting a decline of about 9.8%[22] - Total liabilities decreased to CNY 1,401,874,399.94 in Q1 2022 from CNY 1,545,298,934.37 in Q1 2021[25] - The company's non-current assets totaled approximately RMB 3.13 billion, down from RMB 3.14 billion, indicating a decrease of about 0.5%[22] - The company’s short-term borrowings decreased significantly to RMB 110 million from RMB 234.5 million, a reduction of approximately 53%[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 35,836[11] - The total number of shares held by the top ten unrestricted shareholders is 176,173,467 shares by Jiangsu Kangyuan Group Co., Ltd., accounting for a significant portion of the company's equity[14] - The company plans to cancel 16,452,086 repurchased shares to reduce registered capital, which was approved in the board meeting on January 12, 2022[16] Research and Development - Research and development expenses for the period amounted to CNY 144,196,379.61, a 39.18% increase from CNY 103,601,243.98 in the same period last year[10] - Research and development expenses for Q1 2022 amounted to CNY 144,196,379.61, an increase from CNY 103,601,243.98 in Q1 2021[25] Cash Flow Management - The company reported a net cash flow from operating activities of CNY 79,139,904.88, with no year-on-year comparison available[5] - In Q1 2022, Jiangsu Kangyuan Pharmaceutical Co., Ltd. reported cash inflows from operating activities of approximately CNY 1.12 billion, a 30% increase from CNY 857.75 million in Q1 2021[30] - The net cash flow from operating activities was CNY 79.14 million, compared to a negative CNY 26.92 million in the same period last year, indicating a significant turnaround[30] - Cash outflows for purchasing goods and services increased to CNY 280.10 million from CNY 134.56 million, reflecting a 108% rise year-over-year[30] - Investment activities generated a net cash outflow of approximately CNY 168.37 million, worsening from a net outflow of CNY 98.57 million in Q1 2021[31] - Cash and cash equivalents at the end of Q1 2022 stood at CNY 721.91 million, up from CNY 434.01 million at the end of Q1 2021, marking a 66% increase[31] - The company reported cash inflows from investment activities totaling CNY 282.13 million, down from CNY 406.67 million in the previous year[31] - Total cash outflows from financing activities decreased to CNY 126.30 million from CNY 400.31 million, indicating a reduction in financing costs[31] - The company did not receive any cash from new investments or borrowings in Q1 2022, compared to CNY 191 million in Q1 2021[31] - The net increase in cash and cash equivalents for the quarter was a decrease of CNY 215.53 million, an improvement from a decrease of CNY 334.81 million in the same quarter last year[31] - Jiangsu Kangyuan Pharmaceutical's cash flow management reflects a strategic focus on improving operational efficiency and reducing financing dependency[30] Market Position - The company’s unique product, "Re Du Ning Injection," was included in the national treatment plan for severe COVID-19 cases, enhancing its market position[18]

Financial Performance - As of December 31, 2021, the company's distributable profit amounted to CNY 3,408,882,325.46[5] - The company achieved operating revenue of CNY 3,648,570,084.33 in 2021, representing a year-on-year increase of 20.34%[22] - Net profit attributable to shareholders reached CNY 320,543,630.32, up 21.92% compared to the previous year[22] - The net cash flow from operating activities was CNY 908,295,889.33, reflecting a growth of 29.55% year-on-year[22] - The company reported a basic earnings per share of CNY 0.56, an increase of 27.27% from CNY 0.44 in 2020[22] - The total assets at the end of 2021 were CNY 6,018,019,235.83, a decrease of 1.64% from the previous year[22] - The company reported a total shareholding of 17,005,612 shares at the end of the reporting period, with no changes during the year[150] - The total revenue for the company was CNY 361,362.19 million, with a year-on-year increase of 21.08%[104] - The gross profit margin for the company was 72.07%, showing a decrease of 1.23% compared to the previous year[104] Shareholder Returns - The company decided not to distribute cash dividends or issue bonus shares for the year, opting to use undistributed profits to supplement working capital[5] - The total amount used for share repurchase from February 19, 2021, to July 30, 2021, was CNY 179,999,151.88, which is considered as cash dividends[5] - The company plans not to distribute cash dividends for the fiscal year 2021 to ensure normal operations and long-term development[179] - The total amount used for share repurchase during the year was approximately ¥179.99 million, which is considered as cash dividends for the purpose of calculating the relevant ratio[179] Risk Management - The company reported no significant risks that could materially affect its operations during the reporting period[6] - The company has outlined various potential risks and corresponding countermeasures in the report[6] - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[6] - There were no violations of decision-making procedures regarding external guarantees during the reporting period[6] - The company faces risks related to product quality control, market access, and R&D, necessitating a proactive approach to policy changes and maintaining product advantages[134] Corporate Governance - All board members attended the board meeting, ensuring the integrity of the annual report[4] - The company received a standard unqualified audit report from Lixin Certified Public Accountants[4] - The board of directors is structured to comply with legal requirements, with independent directors adhering to regulations and providing independent opinions on significant matters[139] - The company has implemented a robust information disclosure system to ensure transparency and prevent insider trading, maintaining equal access to information for all shareholders[141] - The company actively engages with investors through various communication channels, respecting their rights and balancing interests among stakeholders[142] Research and Development - The company is focused on expanding its product offerings in the traditional Chinese medicine sector, with several new products under development[92] - The company has established an advanced drug R&D system, focusing on developing innovative drugs with clinical advantages and integrating cutting-edge life science technologies[54] - The company has received clinical trial approval for Jin Zhen Oral Liquid and has expanded its application scope, indicating a strategic move to enhance market presence[112] - The company is developing KYS202002A for multiple myeloma, currently in preclinical research, showcasing its commitment to advancing oncology treatments[108] - The company has established several national-level research platforms, enhancing its collaborative innovation with top research institutions[66] Social Responsibility - In 2021, the company invested a total of 1,561.50 million CNY in social responsibility initiatives, including 1,351.50 million CNY for educational donations and 185 million CNY for disaster relief[199] - The company allocated 25 million CNY specifically for targeted poverty alleviation efforts[200] - The company actively engaged in social responsibility activities, enhancing employee awareness and participation through various initiatives[199] - The company plans to continue its charitable activities, including educational support and assistance for the elderly[198] - The company reported a total of 180 million CNY in material donations as part of its social responsibility efforts[200] Employee Engagement and Development - The company has established an incentive-based compensation system to align employee responsibilities and benefits, promoting sustainable development[170] - The company has a training plan that combines internal and external training to enhance employee skills and management levels[171] - The company emphasizes the importance of employee development and has implemented various programs to foster talent growth and retention[171] - The total number of employees in the parent company and major subsidiaries is 5,045, with 4,405 in the parent company and 640 in major subsidiaries[167] - The company has 19 employees with doctoral degrees and 230 with master's degrees, reflecting a strong educational background among its workforce[169]